These results indicate that GSI interferes with NOTCH activation, as expected, and that in a HuCCT1-xenograft model, Crenigacestat inhibits NOTCH1 signaling but does not display any effect on tumor growth. The gene discussed is NOTCH1; the disease is neoplasm.